IIB Perspectives: Renewed Focus on University Tech Transfer Drives Life Sciences Innovation

2021-04-19T12:01:35-04:00April 19, 2021|

By: Patty Martin, President and CEO, BioCrossroads Indiana universities and companies have played a vital role in the commercialization of insulin, the treatment of prostate cancer, and a reduction in cancer cases caused by the human papillomavirus, among many other therapeutics. Importantly, Hoosier state universities—Indiana University, Purdue University and Notre Dame—have made significant contributions to medical innovation over the past few decades. All of this, including the boost to Indiana’s economy from this wave of innovation, has been supported and enabled by a little-known law with an enormous impact, the University and Small Business Patent Procedures Act of 1980. The Economist characterized the law, more commonly known as the Bayh-Dole Act, an eponymous shorthand referring to the two senators, Birch Bayh and Bob Dole, who co-authored the legislation, as “possibly the most inspired piece of legislation to be enacted in America [...]

BioCrossroads report underscores importance of strong tech transfer programs at Indiana’s research universities

2021-04-05T16:47:42-04:00November 19, 2020|

INDIANAPOLIS, (Nov. 19, 2020) -- BioCrossroads today released a new report, Tech Transfer in Indiana: An Overview for the Life Sciences Industry, a comprehensive resource highlighting the technology transfer processes and approaches used by Indiana University, Purdue University and the University of Notre Dame to facilitate commercialization of research-driven discoveries and innovations. The report also discusses the role of incubators and graduation facilities at research universities, which are increasing in number and importance. “With our three research institutions and thousands of research faculty, Indiana has critical assets necessary to drive innovation. University labs and facilities are especially important for life sciences R&D that require unique space and equipment required to perform complex research,” said Patricia Martin, president and CEO, BioCrossroads. In addition to developing breakthroughs in medical treatments and therapies, Indiana’s three R11 research institutions also generate a substantial amount of [...]

Go to Top